

Express Mail No. EE327628999US
Date of Deposit: January 26, 2000



PATENT APPLICATION
Attorney Docket No. 19721-007 (PMC-7)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Murdin *et al.*
ASSIGNEE : Connaught Laboratories Limited
SERIAL NUMBER : 09/428,122 EXAMINER : Not Yet Assigned
FILING DATE : October 27, 1999 ART UNIT : Not Yet Assigned
FOR : *CHLAMYDIA* ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES
THEREOF

January 26, 2000
Boston, Massachusetts

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

Foreign Patent Documents:

Genset PCT WO 99/27105 June 3, 1999

Other Prior Art – Non Patent Literature Documents:

Kalman, *et al.*, NATURE GENETICS, 21, 385-389 (1999).
Magee, *et al.*, INFECTION AND IMMUNITY, 63:2, 516-521 (1995).
Landers, *et al.*, INFECTION AND IMMUNITY, 59:10, 3774-3777 (1991).
Jackson, *et al.*, ABSTRACTS OF THE 36TH ICAAC, 272 (1996).
Magee, *et al.*, REGIONAL IMMUNOLOGY, 5, 305-311 (1993).
Igletseme, *et al.*, REGIONAL IMMUNOLOGY, 5, 317-324 (1993).
Jones, *et al.*, VACCINE, 13:8, 715-723 (1995).
Pal, *et al.*, INFECTION AND IMMUNITY, 64:12, 5341-5348 (1996).
Hahn, *et al.*, THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 266:2, 225-230 (1991).
Allegra, *et al.*, EUROPEAN RESPIRATORY JOURNAL, 7:2, 2165-2168 (1994).
Björnsson, *et al.*, SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 28:1, 63-69 (1996).
Hahn, THE JOURNAL OF FAMILY PRACTICE, 41:4, 345-351 (1995).

RECEIVED
FEB - 1 2000
TC 3700 MAIL ROOM

Hahn, *et al.*, EPIDEMIOLOGY INFECTION, **117:3**, 513-517 (1996).
Hahn, *et al.*, ANNALS OF ALLERGY, ASTHMA, AND IMMUNOLOGY, **80:1**, 45-49 (1998).
Fong, *et al.*, JOURNAL OF CLINICAL MICROBIOLOGY, **35:1**, 48-52 (1997).
Ramirez, *et al.*, ANNALS OF INTERNAL MEDICINE, **125:12**, 979-982 (1996).
Chiu, *et al.*, CIRCULATION, **96:7**, 2144-2148 (1997).
Campbell, *et al.*, THE JOURNAL OF INFECTIOUS DISEASES, **172:2**, 585-588 (1995).
Kuo, *et al.*, ARTERIOSCLEROSIS AND THROMBOSIS, **13:10**, 1501-1504 (1993).
Kuo, *et al.*, THE JOURNAL OF INFECTIOUS DISEASES, **167:4**, 841-849 (1993).
Melnick, *et al.*, THE AMERICAN JOURNAL OF MEDICINE, **95**, 499-504 (1993).
Saikku, *et al.*, ANNALS OF INTERNAL MEDICINE, **116:4**, 273-278 (1992).
Grayston, *et al.*, THE JOURNAL OF INFECTIOUS DISEASES, **168:5**, 1231-1235 (1993).
Campos, *et al.*, INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, **36:8**, 1477-1491 (1995).
Grayston, *et al.*, THE JOURNAL OF INFECTIOUS DISEASES, **161:4**, 618-625 (1990).
Marrie, CLINICAL INFECTIOUS DISEASES, **18:4**, 501-515 (1994).
Wang *et al.*, CHLAMYDIAL INFECTIONS, 329-333 (1986).
Saikku, *et al.*, THE LANCET, **2:8618**, 983-985 (1988).
Thom, *et al.*, THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, **268:1**, 68-72 (1992).
Linnanmäki, *et al.*, CIRCULATION, **87:4**, 1130-1134 (1993).
Bachmaier, *et al.*, SCIENCE, **283**, 1335-1339 (1999).
Iijima, *et al.*, JOURNAL OF CLINICAL MICROBIOLOGY, **32:3**, 583-588 (1994).
Campbell, *et al.*, JOURNAL OF CLINICAL MICROBIOLOGY, **28:6**, 1261-1264 (1990).
Melgosa, *et al.*, FEMS MICROBIOLOGY LETTERS, **112:2**, 199-204 (1993).
Watson, *et al.*, MICROBIOLOGY, **141**, 2489-2497 (1995).
Watson, *et al.*, NUCLEIC ACIDS RESEARCH, **18:7**, 5299 (1990).
Melgosa, *et al.*, INFECTION AND IMMUNITY, **62:3**, 880-886 (1994).
Takase, *et al.*, JOURNAL OF BACTERIOLOGY, **169:12**, 5692-5699 (1987).
Cagnon, *et al.*, PROTEIN ENGINEERING, **4:7**, 843-847 (1991).
Casey, *et al.*, NUCLEIC ACIDS RESEARCH, **4:5**, 1539-1553 (1977).
Kunkel, PROC. NATL. ACAD. SCI. USA, **82**, 488-492 (1985).
Langeveld, *et al.*, VACCINE, **12:15**, 1994.
Snijders, *et al.*, THE JOURNAL OF GENERAL VIROLOGY, **72:3**, 557-565 (1991).
Dion, *et al.*, VIROLOGY, **179:1**, 474-477 (1990).
Hughes, *et al.*, INFECTION AND IMMUNITY, **60:9**, 3497-3503 (1992).
Wiedmann-Al-Ahmad, *et al.*, CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, **4:6**, 700-704 (1997).
McCafferty, *et al.*, INFECTION AND IMMUNITY, **63:6**, 2387-2389 (1995).
Campbell, *et al.*, INFECTION AND IMMUNITY, **58:1**, 93-97 (1990).
Cotter, *et al.*, INFECTION AND IMMUNITY, **63:12**, 4704-4714 (1995).
Chlamydia Genome Project, <http://chlamydia-www.berkeley.edu:4231>, updated September 23, 1999.
Shor, *et al.*, S AFR MED JOURNAL, **82**, 158-161 (1992).

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application.
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application.
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.


Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Attorney Reference No. 19721-007 (PMC-7).

Respectfully submitted,



Ivor R. Elriff, Registration No. 39,529
Michel Morency, Limited Recognition
Shelby J. Walker, Registration No. 45,192
Attorney(s) for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: January 26, 2000